FATE

Fate Therapeutics Inc. Common Stock (FATE)

Stock · NASDAQ · Health Care

$2.43as of 8/28/2026

Active signals

No technical signal is currently active for this symbol.

Support level
$1.3
Industry
Biotechnology: Biological Products (No Diagnostic Substances)

How Fate Therapeutics Inc. Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$6.65MR&D$107.83M (1622%)SG&A$46.52M (700%)FATE

Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub

Fate Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • FATE
    Fate Therapeutics Inc. Common Stock
    $2.42
    ▼ 4.92%
    Market cap $291.40MP/E
  • SABS
    SAB Biotherapeutics Inc. Common Stock
    $3.79
    ▼ 3.56%
    Market cap $289.80MP/E 26.94
    $1.85$5.15
  • NMRA
    Neumora Therapeutics Inc. Common Stock
    $1.38
    ▼ 6.76%
    Market cap $303.87MP/E
    $0.83015$3.65
  • LCTX
    Lineage Cell Therapeutics Inc. Common Stock
    $1.11
    ▼ 4.31%
    Market cap $276.72MP/E
    $1$2.09
  • AVXL
    Anavex Life Sciences Corp. Common Stock
    $2.98
    ▼ 4.79%
    Market cap $273.38MP/E
    $2.26$10.4
  • EDIT
    Editas Medicine Inc. Common Stock
    $3.15
    ▼ 4.55%
    Market cap $259.45MP/E
    $1.66$4.54
  • SRZN
    Surrozen Inc. Common Stock
    $22.42
    ▼ 6.62%
    Market cap $252.87MP/E
    $10.73$35

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held
69.35M
Total value held
$77.53M
Institutional holders
151
Top holders this quarter
  • Unknown12.87M
  • Unknown10.07M
  • Unknown4.19M
  • Unknown4.12M
  • Unknown3.47M
  • Unknown3.38M
  • Unknown3.00M
  • Unknown2.97M
  • Unknown2.59M
  • Unknown2.26M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.